Menopause affects roughly 40% of a woman's lifespan. Until very recently, it received less than 0.2% of federal health research funding. Those two numbers alone tell you something important about why so many women feel left behind by their care.
A new review in Science is working to close that gap — and it reframes both menopause and hormone therapy as genuine tools for longer, healthier lives. Here's what you need to know.
The science on menopause and hormone therapy has shifted. In November 2025 the FDA began removing most boxed warnings from hormone therapy labels, saying that starting within 10 years of menopause is linked to fewer fractures and lower mortality. Some experts call that evidence thin, so decisions are best made with a clinician.
What's Actually Happening
For years, a single large study shaped how doctors and patients thought about hormone therapy — cautiously, and often with a default toward avoidance. A new review in Science (October 2026) is working to close that gap, and it reframes menopause and hormone therapy as opportunities for healthy aging.
The review's authors count more than 200 distinct MHT formulations — differing by dose, the type of estrogen and progestogen, and timing. Each carries a distinct risk-benefit profile. Treating them as interchangeable isn't just imprecise; the researchers argue it has contributed to women being under-treated, under-informed, and left navigating a transition that spans nearly half their adult lives without adequate tools.
The FDA has changed how it labels hormone therapy. If your last conversation about MHT was more than two years ago, it may be time for a new one.
Why This Matters for You
In announcing the change, the FDA said randomized studies show lower all-cause mortality and fewer fractures in women who start within 10 years of menopause onset, generally before 60. That rests largely on age-subgroup analyses of the Women’s Health Initiative trials, which overall found no difference in all-cause mortality over 18 years (JAMA 2017), and on a Danish trial of about 1,000 recently postmenopausal women (BMJ 2012). The Science review calls for a precision medicine approach, tailoring decisions to a woman’s symptoms, genetics and previous hormone exposures rather than applying population-level caution to everyone.
The nuance is real and worth holding. A 2025 Lancet Healthy Longevity meta-analysis of over one million women found no significant association between MHT and dementia risk overall, neither higher nor lower. Breast cancer risk with long-term combined therapy is a genuine consideration. The emerging consensus is not that MHT is universally good, but that the right MHT for the right person at the right time is a meaningfully different conversation — and one worth having with your doctor.
What You Can Actually Do
- Map your symptom timeline — Note when perimenopause symptoms started and how they've evolved; this timeline is clinically relevant to timing-based decisions about MHT.
- Look beyond the generic prescription — If MHT has been discussed, ask specifically about the route of delivery (patch, gel, oral) and whether a body-identical formulation has been considered.
- Use the research as a conversation opener — Printing or referencing the Science review in a clinical appointment is a legitimate way to signal that you want a precision-based discussion, not a one-size-fits-all answer.
Q&A with the Coach
Why did it take so long for the science to get here?
In 2024, the US National Institutes of Health spent about 0.1% of its research budget on menopause-specific research, which tells you how systematically under-resourced this area has been.
My doctor seemed dismissive when I brought up hormones. What do I do?
Bring evidence — literally. The 2026 Science review is a peer-reviewed, high-impact publication that reframes MHT as a precision medicine question, not a blanket risk. Asking specifically about timing, formulation options, and your individual risk profile signals that you're looking for a clinical conversation, not a generic answer.
Is body-identical or bioidentical hormone therapy different from standard MHT?
The terminology can get slippery, so it's worth being precise with your doctor. Regulated body-identical hormones — like estradiol patches or micronised progesterone — are approved and their profiles are included in the research base. Compounded bioidentical hormones from unregulated sources are a different category, with less evidence and less regulatory oversight.
What does 'precision medicine' actually mean for menopause care?
It means tailoring MHT decisions to the individual rather than applying a population-level average to everyone. That includes considering your symptom pattern and timing, your cardiovascular and bone health baseline, your family history, and potentially your genetics — rather than offering the same conversation to every woman at the same age.
I'm 58 and postmenopausal. Is it too late to have this conversation?
The evidence is clearest for women who initiate MHT within 10 years of menopause onset, and more mixed for those starting later — so timing does matter and your clinician needs to factor that in. That said, there are bone and symptom-related reasons the conversation can still be relevant at 58, and a clinician who specialises in this area is better placed than a general practitioner to help you weigh that.
The research framing menopause as a healthy ageing opportunity isn't wishful thinking — it's published in some of the most rigorous journals in medicine. What's changing is not just the evidence but the expectation of what informed, personalised care should look like.
You don't have to navigate this on generalised caution and outdated warnings. The conversation has changed. It's worth finding a clinician who knows it.
What do you think?
The science on women's health in this life stage is moving fast. new30's newsletter tracks it so you don't have to start from scratch every time — sign up and we'll bring the signal, not the noise.
References: Science
Science (journal) — Reframing menopause and MHT as opportunities for healthy aging (2025):
The Lancet Healthy Longevity — MHT and risk of mild cognitive impairment or dementia: systematic review and meta-analysis (2025):
The Lancet Obstetrics, Gynaecology & Women's Health — From silence to science: the future of menopause research (2025):
Created with AI assistance